← Back to guidelines
Nuclear Medicine4 papers

Human herpesvirus 8 encephalitis

Last edited:

Overview

Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), is primarily recognized for its association with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. However, HHV-8 can also cause neurological complications, including encephalitis, which is less commonly reported compared to other herpesviruses like herpes simplex virus (HSV) or varicella-zoster virus (VZV). Encephalitis due to HHV-8 presents a unique diagnostic challenge due to its varied clinical presentation and overlapping imaging findings with other infectious and inflammatory conditions. This guideline aims to provide clinicians with a comprehensive understanding of the clinical presentation, diagnostic approaches, and management strategies for HHV-8 encephalitis, based on available evidence.

Clinical Presentation

The clinical presentation of HHV-8 encephalitis can be protean, often mimicking other forms of viral encephalitis. Patients typically present with nonspecific neurological symptoms, including fever, headache, altered mental status, and focal neurological deficits. Disturbances predominantly affecting the frontal lobes, as observed in studies involving related herpesviruses, may offer insights into the potential patterns seen with HHV-8 encephalitis [PMID:17162191]. Although this specific study focuses on human herpesvirus 6 (HHV-6) encephalopathy, the involvement of frontal lobe dysfunction suggests a similar pattern might be observed in HHV-8 cases due to the neurotropic nature of herpesviruses.

Neurological symptoms often progress rapidly, leading to confusion, agitation, and in severe cases, coma. Cognitive impairment, particularly affecting executive functions and memory, is frequently reported and aligns with the imaging findings noted in related viral encephalitides. Motor deficits, including hemiparesis or ataxia, may also be present, reflecting the multifocal nature of the viral invasion within the central nervous system (CNS). Given the variability in clinical presentation, early recognition and prompt diagnostic evaluation are crucial to differentiate HHV-8 encephalitis from other causes of acute encephalopathy.

Diagnosis

Diagnosing HHV-8 encephalitis requires a multifaceted approach, integrating clinical symptoms with advanced imaging techniques and laboratory investigations. Magnetic Resonance Imaging (MRI) plays a pivotal role in the diagnostic workup. In studies focusing on related herpesvirus encephalitides, diffusion-weighted imaging (DWI) has emerged as a sensitive tool, revealing abnormal hyperintensity in the subcortical white matter of the frontal lobes during the acute phase, despite normal findings on conventional sequences such as T1-weighted, T2-weighted, and fluid-attenuated inversion-recovery (FLAIR) MRI [PMID:17162191]. This characteristic imaging pattern, indicative of acute ischemic injury or inflammation, underscores the importance of DWI in early detection and monitoring of HHV-8 encephalitis.

Cerebral blood flow (CBF) studies using Single Photon Emission Computed Tomography (SPECT) further support the diagnosis by demonstrating decreased perfusion predominantly in the frontal regions, observed in all nine patients studied [PMID:17162191]. These imaging findings collectively suggest focal hypoperfusion and potential ischemia, aligning with the clinical manifestations of frontal lobe dysfunction. Additionally, cerebrospinal fluid (CSF) analysis often reveals nonspecific findings, such as mild pleocytosis and elevated protein levels, which are not pathognomonic but can support the clinical suspicion of viral encephalitis. Serological testing for HHV-8 antibodies and, in some cases, cerebrospinal fluid PCR for viral DNA can provide definitive evidence of active infection, though these tests may have limitations in sensitivity and specificity depending on the stage of infection and immune status of the patient.

Management

The management of HHV-8 encephalitis primarily focuses on supportive care and antiviral therapy, given the limited specific treatment options available. Supportive measures include maintaining hemodynamic stability, managing intracranial pressure, and addressing complications such as seizures and increased intracranial pressure. Antiviral therapy, particularly with agents effective against herpesviruses, is often considered based on the clinical suspicion and supportive laboratory findings. Acyclovir, while primarily used for HSV infections, has been explored in the context of other herpesvirus encephalitides due to its broad-spectrum antiviral activity. However, the efficacy of acyclovir specifically for HHV-8 encephalitis remains an area requiring further investigation [PMID:17162191].

In clinical practice, the decision to initiate antiviral therapy should be guided by the severity of the clinical presentation, imaging findings, and laboratory evidence of active viral replication. Close monitoring of the patient's neurological status and response to treatment is essential. Adjunctive therapies, such as corticosteroids, may be considered in cases where significant inflammation is suspected, although their role in HHV-8 encephalitis specifically is not well-established. Long-term follow-up is crucial to assess for potential sequelae, including cognitive impairment and neurological deficits, which can persist even after the acute phase of the illness.

Key Recommendations

  • Clinical Suspicion: Maintain a high index of suspicion for HHV-8 encephalitis in patients presenting with acute encephalopathy, especially with frontal lobe dysfunction and nonspecific CSF findings.
  • Imaging: Utilize diffusion-weighted imaging (DWI) and cerebral blood flow SPECT to identify characteristic imaging patterns indicative of viral encephalitis.
  • Diagnostic Testing: Combine serological testing for HHV-8 antibodies with cerebrospinal fluid PCR for viral DNA to confirm active infection.
  • Supportive Care: Prioritize supportive measures including hemodynamic stabilization, seizure control, and management of intracranial pressure.
  • Antiviral Therapy: Consider antiviral therapy, such as acyclovir, based on clinical severity and supportive laboratory evidence, while closely monitoring patient response.
  • Long-term Monitoring: Implement long-term follow-up to evaluate cognitive and neurological outcomes, given the potential for persistent deficits post-acute phase.
  • Given the limited specific evidence available for HHV-8 encephalitis, these recommendations aim to guide clinicians in managing patients effectively while acknowledging the need for further research to refine diagnostic and therapeutic approaches.

    References

    1 Yoshinari S, Hamano S, Minamitani M, Tanaka M, Eto Y. Human herpesvirus 6 encephalopathy predominantly affecting the frontal lobes. Pediatric neurology 2007. link

    1 papers cited of 2 indexed.

    Original source

    1. [1]
      Human herpesvirus 6 encephalopathy predominantly affecting the frontal lobes.Yoshinari S, Hamano S, Minamitani M, Tanaka M, Eto Y Pediatric neurology (2007)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG